• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe

BioWorld Asia

Mon, Jul 28, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Self-amplifying mRNA technology underscored for next big pandemic
  • Skin irritation on hands

    Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis ​

    Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted at Fudan University’s Huashan Hospital, the phase III multicenter, randomized, double-blind, active-controlled (secukinumab) trial enrolled 926 patients with moderate to severe plaque psoriasis.
  • Sino to acquire Lanova and pipeline for up to $950M

  • 34 mainland China biotechs file for Hong Kong IPO in H1 2025

  • Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

  • Hengrui/Kailera obesity asset delivers solid weight loss in phase III

  • Australia awards AU$100M in grants to biopharma/med-tech incubators

  • News in brief

  • Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis ​

    Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted at Fudan University’s Huashan Hospital, the phase III multicenter, randomized, double-blind, active-controlled (secukinumab) trial enrolled 926 patients with moderate to severe plaque psoriasis.
  • Sino to acquire Lanova and pipeline for up to $950M

    Sino Biopharmaceutical Ltd. agreed to fully acquire Lanova Medicines Ltd. by buying an additional 95.09% stake in Lanova at a valuation of up to $950.92 million. Considering Lanova’s estimated cash and deposit of $450 million, Hong Kong-headquartered Sino agreed to pay $500.9 million to Lanova on the date of the transaction, set to close within 30 days of all conditions being satisfied, or July 31, 2025.
  • 34 mainland China biotechs file for Hong Kong IPO in H1 2025

    Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
  • Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

    In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress disorder (PTSD) treatment did not show enough efficacy. Had the adcom felt otherwise, the path may have been smoother for a new treatment in an indication that hasn’t seen regulatory advancement in decades. The committee’s conclusion, however, is not binding on the FDA, which will make its own decision whether to approve.
  • Hengrui/Kailera obesity asset delivers solid weight loss in phase III

    A glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist developed by Jiangsu Hengrui Pharmaceuticals Co. Ltd. and licensed by Kailera Therapeutics Inc. has shown a mean weight loss of 19.2% at the 6-mg dose with no plateau over 48 weeks in a phase III trial conducted in China.
  • Australia awards AU$100M in grants to biopharma/med-tech incubators

    The Australian government has awarded nearly AU$100 million (US$64.65 million) in grant funding to three biopharma/med-tech incubators to support emerging Australian biopharma and med-tech startups.
  • News in brief

    BioWorld Asia briefs for July 22, 2025
  • For big pharma, China is a shopper’s dream

    Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing pressures on drugs. China’s out-licensing deals grew to represent 32% of global deals in the first half of 2025, according to a Jefferies report on China dealmaking.
  • In ongoing mRNA evolution, SML Biopharm sights new cancer vaccines

    SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two candidates for cervical and head and neck cancers caused by human papillomavirus (HPV) infection.
  • Biocon wins first FDA interchangeable label of Novolog biosimilar

    The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo Nordisk A/S’ Novolog (insulin aspart), a rapid-acting diabetes medication.
  • June FDA approvals jump, led by three new NMEs

    The U.S. FDA approved 22 drugs in June, tying with March for the highest number of approvals and a jump from 15 approvals in May. The FDA approved 107 drugs in the first half (H1) of 2025, making it the third-highest total for this period in BioWorld’s records, trailing 118 approvals in 2024 and 108 in 2020.

BioWorld Insider Podcast

Play buttonRobert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.
Listen now

Analysis and data insight

  • Hand, stylus pointing at graph on screen

    Biopharma financings up from a weak Q1 but fall short of past Q2 highs in 2025

    Financings
    Historically, Q2 has often been one of the strongest quarters for biopharma financing, but 2025’s figures suggest a more cautious investment climate. Biopharma companies raised $16.02 billion in the second quarter (Q2) of 2025, a modest increase from the $13.11 billion brought during Q1. While the...
  • International currency symbols

    Biopharma financings total $28.7B in H1, down 59% from 2024

    Financings
    Biopharma companies raised $7.38 billion across 99 transactions in June 2025, up from $5.55 billion in May and $2.4 billion in April. For the first half of the year (H1), total financings reached $28.74 billion, down 59% from the $70.32 billion raised during the same period in 2024. Although lower...
  • Jerome Kim, of IVI, speaking at the Global Vaccine Forum

    Self-amplifying mRNA technology underscored for next big pandemic

    Cancer
    Experts in mRNA convened at the Global Vaccine Forum (GVF) 2025 to weigh the present and future of vaccine technology, including emerging innovations in self-amplifying mRNA (sa-mRNA) and drug delivery platforms.
  • Multiple myeloma illustration

    Cullinan deals $712M to test Genrix bispecific TCE in autoimmune

    Deals and M&A
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma (MM)-targeting BCMAxCD3 bispecific T-cell engager (TCE) velinotamig from Chongqing Genrix Biopharmaceutical Co. Ltd. via a potential $712 million deal June 4. The plan is to repurpose the cancer drug to autoimmune disease.
More in Analysis and data insight

Today's news in brief

  • Appointments and advancements for July 22, 2025

  • Financings for July 22, 2025

  • In the clinic for July 22, 2025

  • Other news to note for July 22, 2025

  • Regulatory actions for July 22, 2025

Deals and M&A

  • JCR’s third deal with Alexion gives rights to AAV capsids

  • Chugai and Gero partner to tackle age-related diseases

  • Bioversys, Shionogi in CHF529M lung infection collaboration

  • Veritas, Mitsubishi Gas Chemical partner for new ASO candidates

  • After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

  • Henlius licenses Hanchorbio’s phase II checkpoint inhibitor HCB-101

  • Torrent Pharma to buy JB Pharma from KKR in $3B M&A deal

  • Abion strikes $1.3B antibody drug deal with unidentified partner

  • Otsuka licenses Harbour’s bispecific T-cell engager for $670M

  • Avata, Oceanus partner on cannabidiol for epilepsy, schizophrenia

Financings

  • Amyloid plaques on nerve cell

    Illimis $42M series B to spur study of Aβ-clearing fusion protein

    Immune
    Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific fusion protein candidate, into preclinical development for Alzheimer’s disease by the second half of 2025, along with the company’s...
  • Polyactiva raises $25M series C to advance U.S. clinical programs

    Ophthalmic
  • Innovent raises HKD$4.3B to advance R&D pipeline, global expansion

    Cancer
  • Keymed launching Stapokibart, advancing pipeline, with $125M raise

    Monoclonal antibody
  • Transthera raises $25M with Hong Kong IPO; stock up 78% on debut

    Cancer
More in Financings

Australia

  • 3D rendering of CAR T therapy in cell

    Imugene’s allogeneic CD19 CAR T sees 75% response rate

    Clinical
    Immuno-oncology company Imugene Ltd.’s allogeneic, off-the-shelf CD19 CAR T, azercabtagene zapreleucel (azer-cel), has resulted in seven complete responses and three partial responses in a phase Ib trial in relapsed diffuse large B-cell lymphoma patients, according to an interim analysis. The...
  • Medibank first to cover psychedelic treatment in Australia

    Neurology/psychiatric
    Australia’s largest health insurance company, Medibank Private Ltd., is the first to reimburse for psychedelic treatment in Australia, funding Emyria Ltd.’s MDMA (3,4-methylenedioxy-methamphetamine) program for post-traumatic stress disorder offered through the Perth Clinic.
  • Nibec stock soars 30% on $435M peptide deal with US biotech

    Deals and M&A
    Nibec Co. Ltd. announced May 28 the signing of a potential $435 million license deal for NP-201, its phase II-ready peptide-based pulmonary fibrosis therapy candidate, with an undisclosed U.S.-based biotech company.
  • Adalta sees promise in new 'East to West' strategy for T-cell therapies

    Deals and M&A
  • Cynata’s MSC cells show positive results across variety of delivery systems

    Clinical
  • Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200

    Deals and M&A
  • Immutep’s efti shows strong survival data in head and neck cancer

    Clinical
More in Australia

China

  • More Chinese ADCs enter the clinic as biotech race heats up

    Clinical
    China has proved to be a fertile ground for innovation as evidenced by some big deals in the antibody-drug conjugate (ADC) space, and the number of candidates entering clinical trials in China or being advanced in the U.S. by Chinese companies.
  • Circode executives

    Circode applies circRNA to heart disease drug R&D, in vivo CAR T

    Newco news
    Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND clearance in China Jan. 10 and the U.S. on May 30, Circode CEO Chenxiang Tang recently told BioWorld.
  • Wooden stamp with China flag

    China approves Ascentage’s lisaftoclax, its first Bcl-2 inhibitor

    Regulatory
    China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) for treating adults with chronic lymphocytic leukemia/small lymphocytic lymphoma who previously received at least one systemic therapy including Bruton’s...
  • China approves Simcere’s suvemcitug for ovarian cancer

    Regulatory
    China’s National Medical Products Administration gave the green light to Simcere Pharmaceutical Group Ltd.’s Enzeshu (suvemcitug) for treating recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in combination with paclitaxel, liposomal doxorubicin, or topotecan in adults...
  • Wuhan Healthgen gets chance at China IPO with SSE market reforms

    Regulatory
    Wuhan Healthgen Biotechnology Co. Ltd. gained clearance from the Shanghai Stock Exchange July 1 to list under a recently reinstated IPO growth tier geared towards supporting “unprofitable” biotechnology firms.
More in China

Clinical

  • Takeda phase IIIs win; Street still wants a visual on narcolepsy

  • Taiho’s pizuglanstat fails in phase III DMD trial

  • Immuno Cure, Pharmjet partner on needle-free HIV vaccine trial

  • Moderna expands mRNA tech to latent viruses, cancer, rare disease

  • 3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

  • Corestemchemon preps US BLA filing for stem cell ALS therapy

  • Dizal's new chemical entities for lung, blood cancers

  • Daiichi and Merck pull accelerated approval BLA for ADC

  • Anatara takes a second look at Garp after phase II IBS miss

  • Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

Regulatory

  • Xray showing lung cancer on tablet

    FDA approves Dizal’s sunvozertinib for metastatic non-small-cell lung cancer

    Cancer
    Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with locally advanced or metastatic non-small-cell lung cancer with epidermal growth factor receptor...
  • China’s NMPA accepts Carsgen’s NDA for Claudin18.2-targeted CAR T

    Cancer
  • Hong Kong to set up CMPR as medical products authority by 2026

    Asia-Pacific
  • China clears mazdutide as first dual GCG/GLP-1RA for weight loss

    Cardiovascular
  • Jyong’s $20M US IPO to help refile NDA of urological botanic drug

    Financings
More in Regulatory
 

Newco news

  • Drug Farm harvests new immunomodulators with AI-gene editing tech

    Cancer
    Shanghai Yao Yuan Biotechnology Ltd., also known as Drug Farm, is advancing a portfolio of immune-modulating therapies for various indications including hepatitis B virus, hepatocellular cancer and a relatively new rare genetic disease called ROSAH, an acronym for retinal dystrophy, optic nerve...
  • Epimab sells bispecific T-cell engager to Juri in $210M deal

    Analysis and data insight
    Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
  • Samsung Biologics to spin off biosimilar subsidiary Samsung Bioepis

    Analysis and data insight
    Samsung Biologics Co. Ltd. plans to establish a new holding company and to spin off its biosimilar division, Samsung Bioepis Co. Ltd., by October. The corporate restructuring will draw clear lines between Samsung Biologics’ CDMO operations and Samsung Bioepis’ biosimilar business.
  • Alteogen merges two subsidiaries, forming Alteogen Biologics

    Analysis and data insight
  • AP Bio heads to phase I with bispecific for HER2-resistant tumors

    Cancer
  • Japan’s Regcell launches in US with $45.8M to advance Treg platform

    Financings
  • Astellas-Yaskawa JV to build robot-based cell production platform

    Deals and M&A
More in Newco news

Science

  • Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    Biomarkers
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of the consortium which compiled it publish the proteomics signatures of major...
  • Turn on vitamin A pathway and regenerate an ear

    Ear, nose and throat
    Lizards, zebrafish, salamanders and tritons can regrow a tail, a fin, or even an entire limb after amputation. Cut a planarian into pieces, and you will end up with a bunch of them. Researchers at the National Institute of Biological Sciences in...
  • First bespoke gene editing therapy treats rare metabolic disease

    Conferences
    Using a customized gene editing therapy, researchers at the Children’s Hospital of Philadelphia have reported success in treating an infant with a severe metabolic disorder. Kiran Musunuru, Barry J. Gertz Professor for Translational Research in...
  • Nuevocor draws $45M series B for gene therapy in rare heart disease

    Clinical
    Nuevocor Pte. Ltd. has closed a $45 million series B, enabling it to move lead gene therapy NVC-001 into the clinic in the treatment of an inherited form of cardiomyopathy.
  • Commander proteins linked to lysosomal dysfunction in Parkinson’s

    Neurology/psychiatric
    Genes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by scientists at Northwestern University. The discovery also explains why some people who carry a pathogenic variant of the GBA1...
  • Australian researchers discover new compound to treat long COVID

    Infection
    Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans. Developed by researchers at the Walter and Eliza Hall Institute of Medical Research...
More in Science

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • The importance of balancing AI and people in drug development
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO
  • Capricor’s CEO pursues a BLA and talks rare disease
  • The first half of 2024 was strong as M&As and financings dominate

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe